Global Retinal Biologics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Retinal Biologics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Many retinal biologics have been approved by the Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for the treatment of retinal diseases. Advancements in technologies and new mechanism of action for different biologics to treat retinal diseases are anticipated to boost the retinal biologics market.
Retinal Biologics report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Retinal Biologics market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Retinal Biologics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Retinal Biologics key companies include Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc and Amgen Inc, etc. Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc are top 3 players and held % share in total in 2022.
Retinal Biologics can be divided into Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema and Uveitis, etc. Macular Degeneration is the mainstream product in the market, accounting for % share globally in 2022.
Retinal Biologics is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Retinal Biologics industry development. In 2022, global % share of Retinal Biologics went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Retinal Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Spark Therapeutics, Inc
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals, Inc
AbbVie Inc
Johnson & Johnson Services, Inc
Amgen Inc
Segment by Type
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Retinal Biologics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Retinal Biologics introduction, etc. Retinal Biologics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Retinal Biologics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Retinal Biologics report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Retinal Biologics market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Retinal Biologics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Retinal Biologics key companies include Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson & Johnson Services, Inc and Amgen Inc, etc. Spark Therapeutics, Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc are top 3 players and held % share in total in 2022.
Retinal Biologics can be divided into Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema and Uveitis, etc. Macular Degeneration is the mainstream product in the market, accounting for % share globally in 2022.
Retinal Biologics is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Retinal Biologics industry development. In 2022, global % share of Retinal Biologics went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Retinal Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Spark Therapeutics, Inc
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals, Inc
AbbVie Inc
Johnson & Johnson Services, Inc
Amgen Inc
Segment by Type
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Retinal Biologics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Retinal Biologics introduction, etc. Retinal Biologics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Retinal Biologics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.